Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Reinier de Graaf Groep
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06161805CT.gov Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometriosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jnj-54135419 (this asset) | Reinier de Graaf Groep | P3 | B · 60 |
| Cyclic Microgestin 1/20 | Endeavor Health | P4 | BB |
| Rocuronium Ion | Stony Brook University | P4 | BB |
| Danazol | Centre for Endocrinology and Reproductive Medicine, Italy | P4 | BB |
| Ulipristal Acetate | Northwestern University | P4 | BB |
| Continuous Microgestin 1/20 | Endeavor Health | P4 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | University Hospitals Cleveland Medical Center | P4 | BB |
| Goserelin | Aristotle University Of Thessaloniki | P4 | BB |
| Xuefu-Zhuyu | Zhong Wang | P4 | BB |
+21 more in the Endometriosis cohort
Other indications for Jnj-54135419
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Depressive Disorder | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 73 |
| Major Depressive Disorder | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jnj-54135419 in Endometriosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jnj-54135419-endometriosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →